PI3K/AKT Signaling in Cancer

Matthews, L., Orlic-Milacic, M., Thorpe, L., Yuzugullu, H., Zhao, JJ.

This is just an excerpt of a full-length report for this pathway. To access the complete report, please download it at the Reactome Textbook.

30/09/2022

Introduction

Reactome is open-source, open access, manually curated and peer-reviewed pathway database. Pathway annotations are authored by expert biologists, in collaboration with Reactome editorial staff and cross-referenced to many bioinformatics databases. A system of evidence tracking ensures that all assertions are backed up by the primary literature. Reactome is used by clinicians, geneticists, genomics researchers, and molecular biologists to interpret the results of high-throughput experimental studies, by bioinformaticians seeking to develop novel algorithms for mining knowledge from genomic studies, and by systems biologists building predictive models of normal and disease variant pathways.

The development of Reactome is supported by grants from the US National Institutes of Health (P41 HG003751), University of Toronto (CFREF Medicine by Design), European Union (EU STRP, EMI-CD), and the European Molecular Biology Laboratory (EBI Industry program).

Literature references

Fabregat, A., Sidiropoulos, K., Viteri, G., Forner, O., Marin-Garcia, P., Arnau, V. et al. (2017). Reactome pathway analysis: a high-performance in-memory approach. *BMC bioinformatics, 18*, 142. ↗

Sidiropoulos, K., Viteri, G., Sevilla, C., Jupe, S., Webber, M., Orlic-Milacic, M. et al. (2017). Reactome enhanced pathway visualization. *Bioinformatics, 33*, 3461-3467. ↗

Fabregat, A., Jupe, S., Matthews, L., Sidiropoulos, K., Gillespie, M., Garapati, P. et al. (2018). The Reactome Pathway Knowledgebase. *Nucleic Acids Res, 46*, D649-D655. ↗

Fabregat, A., Korninger, F., Viteri, G., Sidiropoulos, K., Marin-Garcia, P., Ping, P. et al. (2018). Reactome graph database: Efficient access to complex pathway data. *PLoS computational biology, 14*, e1005968. ↗

Reactome database release: 82

This document contains 4 pathways (see Table of Contents)

PI3K/AKT Signaling in Cancer ↗

Stable identifier: R-HSA-2219528

Diseases: cancer

Class IA PI3K is a heterodimer of a p85 regulatory subunit (encoded by PIK3R1, PIK3R2 or PIK3R3) and a p110 catalytic subunit (encoded by PIK3CA, PIK3CB or PIK3CD). In the absence of activating signals, the regulatory subunit stabilizes the catalytic subunit while inhibiting its activity. The complex becomes activated when extracellular signals stimulate the phosphorylation of the cytoplasmic domains of transmembrane receptors or receptor-associated proteins. The p85 regulatory subunit binds phosphorylated motifs of activator proteins, which induces a conformational change that relieves p85-mediated inhibition of the p110 catalytic subunit and enables PI3K to phosphorylate PIP2 to form PIP3. The phosphoinositide kinase activity of PI3K is opposed by the phosphoinositide phosphatase activity of PTEN.

PIP3 acts as a messenger that recruits PDPK1 (PDK1) and AKT (AKT1, AKT2 or AKT3) to the plasma membrane. PDPK1 also possesses a low affinity for PIP2, so small amounts of PDPK1 are always present at the membrane. Binding of AKT to PIP3 induces a conformational change that enables TORC2 complex to phosphorylate AKT at a conserved serine residue (S473 in AKT1). Phosphorylation at the serine residue enables AKT to bind to PDPK1 and exposes a conserved threonine residue (T308) that is phosphorylated by PDPK1. AKT phosphorylated at both serine and threonine residues dissociates from the plasma membrane and acts as a serine/threonine kinase that phosphorylates a number of cytosolic and nuclear targets involved in regulation of cell metabolism, survival and gene expression. For a recent review, please refer to Manning and Cantley, 2007.

Signaling by PI3K/AKT is frequently constitutively activated in cancer. This activation can be via gain-of-function mutations in PI3KCA (encoding catalytic subunit p110alpha), PIK3R1 (encoding regulatory subunit p85alpha) and AKT1. The PI3K/AKT pathway can also be constitutively activated by loss-of-function mutations in tumor suppressor genes such as PTEN.

Gain-of-function mutations activate PI3K signaling by diverse mechanisms. Mutations affecting the helical domain of PIK3CA and mutations affecting nSH2 and iSH2 domains of PIK3R1 impair inhibitory interactions between these two subunits while preserving their association. Mutations in the catalytic domain

of PIK3CA enable the kinase to achieve an active conformation. PI3K complexes with gain-of-function mutations therefore produce PIP3 and activate downstream AKT in the absence of growth factors (Huang et al. 2007, Zhao et al. 2005, Miled et al. 2007, Horn et al. 2008, Sun et al. 2010, Jaiswal et al. 2009, Zhao and Vogt 2010, Urick et al. 2011). While AKT1 gene copy number, expression level and phosphorylation are often increased in cancer, only one low frequency point mutation has been repeatedly reported in cancer and functionally studied. This mutation represents a substitution of a glutamic acid residue with lysine at position 17 of AKT1, and acts by enabling AKT1 to bind PIP2. PIP2-bound AKT1 is phosphorylated by TORC2 complex and by PDPK1 that is always present at the plasma membrane, due to low affinity for PIP2. Therefore, E17K substitution abrogates the need for PI3K in AKT1 activation (Carpten et al. 2007, Landgraf et al. 2008).

Loss-of-function mutations affecting the phosphatase domain of PTEN are frequently found in sporadic cancers (Kong et al. 1997, Lee et al. 1999, Han et al. 2000), as well as in PTEN hamartoma tumor syndromes (PHTS) (Marsh et al. 1998). PTEN can also be inactivated by gene deletion or epigenetic silencing, or indirectly by overexpression of microRNAs that target PTEN mRNA (Huse et al. 2009). Cells with deficient PTEN function have increased levels of PIP3, and therefore increased AKT activity. For a recent review, please refer to Hollander et al. 2011.

Because of their clear involvement in human cancers, PI3K and AKT are targets of considerable interest in the development of small molecule inhibitors. Although none of the currently available inhibitors display preference for mutant variants of PIK3CA or AKT, several inhibitors targeting the wild-type kinases are undergoing clinical trials. These include dual PI3K/mTOR inhibitors, class I PI3K inhibitors, pan-PI3K inhibitors, and pan-AKT inhibitors. While none have yet been approved for clinical use, these agents show promise for future therapeutics. In addition, isoform-specific PI3K and AKT inhibitors are currently being developed, and may provide more specific treatments along with reduced side-effects. For a recent review, please refer to Liu et al. 2009.

Literature references

Roberts, TM., Cheng, H., Liu, P., Zhao, JJ. (2009). Targeting the phosphoinositide 3-kinase pathway in cancer. *Nat Rev Drug Discov, 8*, 627-44. ↗

Blumenthal, GM., Dennis, PA., Hollander, MC. (2011). PTEN loss in the continuum of common cancers, rare syndromes and mouse models. *Nat. Rev. Cancer, 11*, 289-301. ↗

Kato, H., Shibata, H., Matsuno, S., Shiiba, K., Han, SY., Kato, S. et al. (2000). Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay. *Cancer Res, 60*, 3147-51. ↗

Liu, Z., Shin, E., Roberts, TM., Wang, L., Loda, MF., Zhao, JJ. (2005). The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. *Proc. Natl. Acad. Sci. U.S.A., 102*, 18443-8. ↗

Zou, TT., Abraham, JM., Kong, D., Horii, A., Yamakawa, H., Suzuki, A. et al. (1997). PTEN1 is frequently mutated in primary endometrial carcinomas. *Nat. Genet., 17*, 143-4. ↗

Editions

2012-07-18	Authored	Orlic-Milacic, M.
2012-08-03	Edited	Matthews, L.
2012-08-13	Reviewed	Zhao, JJ., Yuzugullu, H., Thorpe, L.

Constitutive Signaling by Aberrant PI3K in Cancer ↗

Location: PI3K/AKT Signaling in Cancer

Stable identifier: R-HSA-2219530

Diseases: cancer

Signaling by PI3K/AKT is frequently constitutively activated in cancer via gain-of-function mutations in one of the two PI3K subunits - PI3KCA (encoding the catalytic subunit p110alpha) or PIK3R1 (encoding the regulatory subunit p85alpha). Gain-of-function mutations activate PI3K signaling by diverse mechanisms. Mutations affecting the helical domain of PIK3CA and mutations affecting nSH2 and iSH2 domains of PIK3R1 impair inhibitory interactions between these two subunits while preserving their association. Mutations in the catalytic domain of PIK3CA enable the kinase to achieve an active conformation. PI3K complexes with gain-of-function mutations therefore produce PIP3 and activate downstream AKT in the absence of growth factors (Huang et al. 2007, Zhao et al. 2005, Miled et al. 2007, Horn et al. 2008, Sun et al. 2010, Jaiswal et al. 2009, Zhao and Vogt 2010, Urick et al. 2011).

Literature references

Urick, ME., Rudd, ML., Godwin, AK., Sgroi, D., Bell, DW., Merino, M. (2011). PIK3R1 (p85?) is somatically mutated at high frequency in primary endometrial cancer. *Cancer Res., 71*, 4061-7. ↗

Samuels, Y., Mandelker, D., Schmidt-Kittler, O., Kinzler, KW., Vogelstein, B., Amzel, LM. et al. (2007). The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. *Science, 318*, 1744-8. ↗

Yue, P., Kaminker, JS., Kan, Z., Modrusan, Z., Dbouk, HA., Kenski, DM. et al. (2009). Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation. *Cancer Cell, 16*, 463-74. ↗

Inbar, Y., Miled, N., Hon, WC., Williams, RL., Yan, Y., Backer, JM. et al. (2007). Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. *Science, 317*, 239-42. ↗

Zhao, L., Vogt, PK. (2010). Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase (pI3K): differential interactions with the regulatory subunit p85 and with RAS. *Cell Cycle, 9*, 596-600. ↗

Editions

2012-07-18	Authored	Orlic-Milacic, M.
2012-08-13	Reviewed	Zhao, JJ., Yuzugullu, H., Thorpe, L.

Constitutive Signaling by AKT1 E17K in Cancer ↗

Location: PI3K/AKT Signaling in Cancer

Stable identifier: R-HSA-5674400

Diseases: cancer

While AKT1 gene copy number, expression level and phosphorylation are often increased in cancer, only one low frequency point mutation has been repeatedly reported in cancer and functionally studied. This mutation represents a substitution of a glutamic acid residue with lysine at position 17 of AKT1, and acts by enabling AKT1 to bind PIP2. PIP2-bound AKT1 is phosphorylated by TORC2 complex and by PDPK1 that is always present at the plasma membrane, due to low affinity for PIP2. Therefore, E17K substitution abrogates the need for PI3K in AKT1 activation (Carpten et al. 2007, Landgraf et al. 2008).

Literature references

Falke, JJ., Landgraf, KE., Pilling, C. (2008). Molecular mechanism of an oncogenic mutation that alters membrane targeting: Glu17Lys modifies the PIP lipid specificity of the AKT1 PH domain. *Biochemistry, 47*, 12260-9. ↗

Tucker-Kellogg, G., Lin, A., Blanchard, KL., Carpten, JD., Qian, YW., Moses, TY. et al. (2007). A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. *Nature, 448*, 439-44. ↗

Editions

2012-07-18	Authored	Orlic-Milacic, M.
2012-08-13	Reviewed	Zhao, JJ., Yuzugullu, H., Thorpe, L.

PTEN Loss of Function in Cancer ↗

Location: PI3K/AKT Signaling in Cancer

Stable identifier: R-HSA-5674404

Diseases: cancer

Loss-of-function mutations affecting the phosphatase domain of PTEN are frequently found in sporadic cancers (Kong et al. 1997, Lee et al. 1999, Han et al. 2000), as well as in PTEN hamartoma tumor syndromes (PHTS) (Marsh et al. 1998). PTEN can also be inactivated by gene deletion or epigenetic silencing, or indirectly by overexpression of microRNAs that target PTEN mRNA (Huse et al. 2009). Cells with deficient PTEN function have increased levels of PIP3, and therefore increased AKT activity. For a recent review, please refer to Hollander et al. 2011.

Literature references

Rouhanifard, SH., le Sage, C., Hambardzumyan, D., Brennan, C., Holland, EC., Sohn-Lee, C. et al. (2009). The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo. *Genes Dev., 23*, 1327-37. ↗

Blumenthal, GM., Dennis, PA., Hollander, MC. (2011). PTEN loss in the continuum of common cancers, rare syndromes and mouse models. *Nat. Rev. Cancer, 11*, 289-301. ↗

Lunetta, KL., Marsh, DJ., Richardson, AL., Coulon, V., Chompret, A., Eeles, RA. et al. (1998). Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. *Hum. Mol. Genet., 7*, 507-15. ↗

Kato, H., Shibata, H., Matsuno, S., Shiiba, K., Han, SY., Kato, S. et al. (2000). Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay. *Cancer Res, 60*, 3147-51. ↗

Georgescu, MM., Pavletich, NP., Shi, Y., Maehama, T., Pandolfi, P., Yang, H. et al. (1999). Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. *Cell, 99*, 323-34. ↗

Editions

2012-07-18	Authored	Orlic-Milacic, M.
2012-08-13	Reviewed	Zhao, JJ., Yuzugullu, H., Thorpe, L.

Table of Contents